Roivant Sciences (NASDAQ:ROIV) (NASDAQ: ROIV) is a biopharmaceutical company established in 2014 that specializes in accelerating the development and commercialization of promising therapeutic candidates. Adopting a “vant” model, Roivant identifies molecules that have been deprioritized by larger pharmaceutical companies and allocates dedicated resources and expertise through independent subsidiaries. This approach enables rapid decision-making and focused execution, with the goal of advancing innovative treatments across a range of therapeutic areas.
The company’s portfolio of “Vants” spans multiple specialties, including neurology, immunology, women’s health, dermatology, urology and rare diseases. Notable subsidiaries include Myovant Sciences, which concentrates on reproductive and prostate health, Immunovant for autoimmune disorders, and Axovant for neurodegenerative conditions. Each subsidiary maintains its own scientific and commercial teams, while leveraging Roivant’s shared infrastructure in areas such as data analytics, regulatory strategy and manufacturing partnerships to streamline operations and reduce development timelines.
Headquartered in Basel, Switzerland, with major offices in New York and Boston, Roivant operates research and development facilities across North America, Europe and Asia. The company engages in strategic collaborations with academic institutions, contract research organizations and industry partners to expand its pipeline and access specialized technologies. In addition to its biopharmaceutical activities, Roivant has established Datavant, a health data infrastructure venture that focuses on securing and connecting disparate patient-level data to support real-world evidence generation and clinical research.
Under the leadership of Founder, President and Chief Executive Officer Vivek Ramaswami, Roivant has grown into a global organization employing seasoned industry executives, scientists and data experts. The executive team emphasizes agile governance, rigorous scientific evaluation and a patient-focused mindset to drive value and deliver new treatment options. With a diversified pipeline and a capital-efficient operating model, Roivant Sciences continues to pursue transformational therapies across a broad spectrum of unmet medical needs.
